Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 plus pegylated interferon alfa-2b and ribavirin in treatment-naive HCV/HIV-1 coinfected adults
ACTRN12612001189819Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BIT225 in hepatitis C virus infection and Human immunodeficiency virus infection type 1, sponsored by Biotron Ltd. Primary endpoint: Safety and tolerability of BIT225 with pegylated interferon alfa-2b, ribavirin and ART. Started Feb 2013; status: completed.
02
Drugs
BIT225
03
Conditions
hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12612001189819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001189819.